What is Cellenkos?
Cellenkos is a clinical-stage biotechnology firm dedicated to pioneering novel allogeneic Treg cell therapies. The company's focus lies in developing transformative treatments for autoimmune and inflammatory disorders. Established in 2016 and headquartered in Texas, United States, Cellenkos is strategically positioned to address unmet medical needs through its innovative cellular therapy platform.
How much funding has Cellenkos raised?
Cellenkos has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for Cellenkos?
With the recent influx of capital, Cellenkos is poised for accelerated growth and the advancement of its therapeutic candidates through clinical trials. This large-scale, late-stage funding is indicative of strong investor confidence in the company's technology and its potential to disrupt the treatment landscape for autoimmune and inflammatory diseases. Future strategic initiatives will likely concentrate on expanding clinical development programs, enhancing manufacturing capabilities, and potentially forging key partnerships to broaden market access.
See full Cellenkos company page